New York, May 20, 2026, 12:03 (EDT)
Mesa Laboratories Inc. shares rose about 2% to $101.78 in late Wednesday morning trading, with volume near 88,900 shares, as the small-cap life-science tools company moved ahead of next week’s year-end report. The stock traded between $98.52 and $102.52.
The timing matters. Mesa is due to report fiscal fourth-quarter and full-year results on May 27, covering the year ended March 31, with the release scheduled for about 6 a.m. Eastern time.
It will be the company’s first full-year report since Siddhartha Kadia took over as president and chief executive on April 13. Mesa said in March that Gary Owens would step down after leading the company since 2017, and Chair John Sullivan called Kadia a “proven global executive” in life sciences. Kadia said he was joining at an “important time.” Mesa Labs
Investors have a narrow set of fresh facts to work with before the earnings print. Mesa’s last reported quarter showed revenue up 3.6%, operating income up 38% to $8.0 million, and adjusted operating income — profit adjusted to exclude certain non-cash and unusual items — at 26.2% of revenue. Then-CEO Owens cited “stable markets across Europe and North America” and said the company expected momentum to continue into the fourth quarter. Mesa Labs
The stock’s move also came in a stronger small-cap market. IWM, an exchange-traded fund that tracks the Russell 2000 small-company index, rose about 2.3%, while the Nasdaq 100 tracker QQQ gained about 1.4% and the S&P 500 tracker SPY rose about 0.9%.
Large life-science tools peers were mixed, giving Mesa some company but not a clean read. Danaher rose about 0.5% and Agilent was up about 0.2%, while Thermo Fisher Scientific slipped about 0.9%.
Mesa is smaller and thinner-traded than those firms, so the stock can move on less obvious flows. The company sells life-science tools and quality-control products used in regulated pharmaceutical, healthcare and medical-device markets.
There is also a modest income angle. Mesa declared a regular quarterly dividend of 16 cents a share, payable June 15 to holders of record at the close of business on May 29.
The risk is that next week’s report may not back up Wednesday’s bid. In its latest quarterly filing, Mesa said Clinical Genomics sales were still hurt by China trade tensions and weak macro conditions, and that China challenges were expected to persist into fiscal 2027; tariffs and a weaker dollar also cut year-to-date gross margin by about 0.8 percentage points.
Clinical Genomics remains the soft spot. The unit’s revenue fell 7.1% in the December quarter, driven by lower sales to customers in China, though sales outside China rose. If demand in that market worsens, Mesa said the unit could face future impairment losses, meaning an accounting write-down of goodwill or intangible assets.
That leaves the stock set up for a fairly direct test: whether Kadia’s first year-end update can show enough growth in biopharmaceutical development and sterilization controls to offset China, tariffs and currency drag. For now, traders were marking the shares higher before the numbers.
